FY2025 EPS Estimate for Gilead Sciences Increased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Gilead Sciences in a report issued on Friday, April 25th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings of $7.96 per share for the year, up from their previous forecast of $7.93. Cantor Fitzgerald has a “Overweight” rating and a $125.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

Several other research firms have also recently issued reports on GILD. Morgan Stanley increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, April 25th. Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $109.43.

Gilead Sciences Stock Down 2.0 %

Shares of Gilead Sciences stock opened at $104.21 on Monday. Gilead Sciences has a one year low of $62.07 and a one year high of $119.96. The company has a market cap of $129.76 billion, a P/E ratio of 281.65, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a fifty day moving average of $109.07 and a two-hundred day moving average of $98.52.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.03%. Gilead Sciences’s payout ratio is 66.53%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the transaction, the chief financial officer now directly owns 171,223 shares of the company’s stock, valued at $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 302,785 shares of company stock worth $30,540,875. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently made changes to their positions in the business. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the first quarter worth approximately $25,000. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Finally, Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.